Daniel Lee Liebman is a Boston, Massachusetts based male Ophthalmologist who is specialized in Ophthalmology. Active license number of Daniel Lee Liebman is 1014182 for Ophthalmology in Massachusetts. Daniel Lee Liebman is medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, patients can be prescribed vision services, including glasses and contact lenses.
Complete Profile:
Daniel Lee Liebman speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Ophthalmology
Credentials:
MD
Gender:
Male
Practice Address:
243 Charles St, Boston, Massachusetts, 02114-3096
Phone:
617-573-3689
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1467912758
NPI Enumeration Date:
22 Mar, 2019
NPI Last Update On:
29 Jun, 2023
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Daniel Lee Liebman are as mentioned below.
License Number
Specialization
State
Status
1014182
Ophthalmology
Massachusetts
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
243 Charles St, Boston, Massachusetts
Zip:
02114-3096
Phone Number:
617-573-3689
Fax Number:
--
Patients can reach Daniel Lee Liebman at 243 Charles St, Boston, Massachusetts or can call to book an appointment on 617-573-3689. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.